J Oral Med Oral Surg
Volume 24, Number 1, January 2018
|Page(s)||40 - 43|
|Section||Cas clinique et revue de la littérature / Up-to date review and case report|
|Published online||25 May 2018|
Up-to Date Review and Case Report
Management of orofacial granulomatosis: a case report
CHU Rouen, Service de chirurgie orale Hôpital St Julien,
2 CHU Toulouse, Service de Dermatologie Hôpital Larrey, 31000 Toulouse, France
3 Université de Toulouse III, 31000 Toulouse, France
4 CHU Toulouse, Service Odontologie, Consultation, pluridisciplinaire de Pathologies de la muqueuse buccale, 31000 Toulouse, France
5 CNRS UMR 5213, 31000 T oulouse, France
* Correspondence: firstname.lastname@example.org
Accepted: 5 September 2017
Introduction: Orofacial granulomatosis is characterized by recurrent swelling affecting the lips, cheeks, and tongue. The rarity of this pathology and the lack of consensus in therapeutic management make the reporting of this clinical case relevant. Observation: A 48-year-old man consulted for labial and gingival orofacial granulomatosis. The treatment consisted of 40 mg/L injections of triamcinolone acetonide once weekly for 3 weeks. The symptoms improved after 1 week of treatment. Comments: The usual treatment for this condition targets the inflammation caused by the lesion. Corticosteroids (clobetasol, triamcinolone acetonide, prednisolone), monoclonal antibodies (infliximab, adalimumab), or TNF-α inhibitors are commonly used. Symptom recurrenceis frequently observed after treatment with corticosteroids. Biotherapies are often used as a second-line treatment. Conclusion: Orofacial granulomatosis symptoms are rare and difficult to diagnose due to its varying manifestations. Common treatments target one of the steps of the inflammatory response. The detection of specific cellular markers is a way to enable a more precise etiological diagnosis and allows for a more targeted therapy.
Key words: orofacial granulomatosis / cheilitis / triamcinolone / oral dermatology
© The authors, 2018
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.